An Exploratory Study Evaluating Changes in Chemotherapy-Induced Peripheral Neuropathy (CIPN)-Related Symptoms and Usability Following Foot-Cooling Device Use in Patients Receiving Chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011543

Enrollment

Registered

2026-01-27

Start date

2026-03-31

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(Foot-Cooling Device ) : 1) Platinum-Based Chemotherapy ?When platinum-based chemotherapy is administered in the hospital at each treatment cycle, the recommended duration of foot cooling device

this is not mandatory. ?The duration of foot cooling application is up to 12 weeks (±2 weeks) from the first dose of lazertinib. Osimertinib ?Osimertinib is an orally administered anticancer agent tak

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who have provided written informed consent prior to participation in this study. 2)Patients aged 19 years or older and less than 80 years at the time of enrollment. 3)Patients scheduled to receive first-time treatment with platinum-based chemotherapy (including taxanes, vinca alkaloids, etc.) or EGFR tyrosine kinase inhibitors (EGFR-TKIs) (lazertinib or osimertinib).

Exclusion criteria

Exclusion criteria: 1)Patients with a prior history of chemotherapy (including neoadjuvant or adjuvant therapy) or EGFR-TKI treatment before enrollment. 2)Patients with pre-existing symptoms of chemotherapy-induced peripheral neuropathy (CIPN) at the time of enrollment. 3)Patients with an active infection (e.g., open wounds, inflammation) at the site where the foot cooling device would be applied at the time of enrollment. 4)Patients with a history of peripheral neuropathy (including diabetic, drug-induced, or traumatic neuropathy). 5)Patients deemed inappropriate for study participation at the investigator’s discretion.

Design outcomes

Primary

Measure	Time frame
Changes in subjective symptoms related to chemotherapy-induced peripheral neuropathy (CIPN) after the use of a foot cooling device	—

Secondary

Measure	Time frame
Usability and patient satisfaction with the use of a foot cooling device;Discomfort and adverse events related to foot cooling device use;Collection of preliminary data for the design of a subsequent study	—

Countries

Korea, Republic of

Contacts

Public ContactJae Cheol Lee

Asan Medical Center

jclee@amc.seoul.kr+82-2-3010-3208

Outcome results